o NoneEntity Type
0001411685
Excaliber Enterprises, Ltd.
 
x Corporation
o Limited Partnership
o Limited Liability Company
o General Partnership
o Business Trust
o Other
Name of Issuer
 VistaGen Therapeutics, Inc.
Jurisdiction of Incorporation/OrganizationNEVADA 
Year of Incorporation/Organization
  x Over Five Years Ago
  o Within Last Five Years (Specify Year)  
  o Yet to Be Formed 



2. Principal Place of Business and Contact Information
Name of Issuer 
 VistaGen Therapeutics, Inc. 
Street Address 1Street Address 2
 343 Allerton Avenue 
CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
 South San Francisco CALIFORNIA 94080 650-577-3600 



3. Related Persons
Last NameFirst NameMiddle Name
SinghShawnK.
Street Address 1Street Address 2
343 Allerton Avenue
CityState/Province/CountryZIP/Postal Code
South San FranciscoCALIFORNIA94080
Relationship: x Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
DotsonJerroldD.
Street Address 1Street Address 2
343 Allerton Avenue
CityState/Province/CountryZIP/Postal Code
South San FranciscoCALIFORNIA94080
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
SnodgrassH.Ralph
Street Address 1Street Address 2
343 Allerton Avenue
CityState/Province/CountryZIP/Postal Code
South San FranciscoCALIFORNIA94080
Relationship: x Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
SaxeJonS.
Street Address 1Street Address 2
343 Allerton Avenue
CityState/Province/CountryZIP/Postal Code
South San FranciscoCALIFORNIA94080
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

 
Last NameFirst NameMiddle Name
UnderdownBrianJ.
Street Address 1Street Address 2
343 Allerton Avenue
CityState/Province/CountryZIP/Postal Code
South San FranciscoCALIFORNIA94080
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
GinJerryB.
Street Address 1Street Address 2
343 Allerton Ave.
CityState/Province/CountryZIP/Postal Code
South San FranciscoCALIFORNIA94080
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
SmithMarkA.
Street Address 1Street Address 2
343 Allerton Ave.
CityState/Province/CountryZIP/Postal Code
South San FranciscoCALIFORNIA94080
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
McPartlandMarkA.
Street Address 1Street Address 2
343 Allerton Ave.
CityState/Province/CountryZIP/Postal Code
South San FranciscoCALIFORNIA94080
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
 

 
Last NameFirst NameMiddle Name
CunninghamAnnK.
Street Address 1Street Address 2
343 Allerton Ave.
CityState/Province/CountryZIP/Postal Code
South San FranciscoCALIFORNIA94080
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

 


4. Industry Group
o Agriculture Health Care o Retailing
 Banking & Financial Services   o Biotechnology o Restaurants
  o Commercial Banking   o Health Insurance Technology
  o Insurance  o Hospitals & Physicians  o Computers
  o Investing  x Pharmaceuticals  o Telecommunications
  o Investment Banking  o Other Health Care  o Other Technology
  o Pooled Investment Fund

    Travel
  o Other Banking & Financial Services o Manufacturing  o Airlines & Airports
 Real Estate  o Lodging & Conventions
  o Commercial  o Tourism & Travel Services
  o Construction  o Other Travel
  o REITS & Finance o Other
  o Residential 
  o Other Real Estate 
o Business Services 
 Energy 
  o Coal Mining 
  o Electric Utilities 
  o Energy Conservation 
  o Environmental Services 
  o Oil & Gas 
  o Other Energy 


5. Issuer Size
Revenue RangeAggregate Net Asset Value Range
o No Revenues o No Aggregate Net Asset Value
o $1 - $1,000,000 o $1 - $5,000,000
o $1,000,001 - $5,000,000 o $5,000,001 - $25,000,000
o $5,000,001 - $25,000,000 o $25,000,001 - $50,000,000
o $25,000,001 - $100,000,000 o $50,000,001 - $100,000,000
o Over $100,000,000 o Over $100,000,000
x Decline to Disclose o Decline to Disclose
o Not Applicable o Not Applicable


6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
o Rule 504(b)(1) (not (i), (ii) or (iii)) o Rule 505
o Rule 504 (b)(1)(i) x Rule 506(b)
o Rule 504 (b)(1)(ii) o Rule 506(c)
o Rule 504 (b)(1)(iii) o Securities Act Section 4(a)(5)
  o Investment Company Act Section 3(c)

7. Type of Filing
x New Notice Date of First Sale 2020-01-24 o First Sale Yet to Occur
o Amendment

8. Duration of Offering
Does the Issuer intend this offering to last more than one year? o Yes x No

9. Type(s) of Securities Offered (select all that apply)
o Pooled Investment Fund Interests o Equity
o Tenant-in-Common Securities o Debt
o Mineral Property Securities x Option, Warrant or Other Right to Acquire Another Security
o Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security o Other (describe)
  


10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? o Yes x No
 
Clarification of Response (if Necessary) 
  

11. Minimum Investment
Minimum investment accepted from any outside investor$ 250000 USD

12. Sales Compensation
RecipientRecipient CRD Number o None
  
(Associated) Broker or Dealer o None(Associated) Broker or Dealer CRD Number o None
  
Street Address 1Street Address 2
  
City State/Province/CountryZIP/Postal Code
   
State(s) of Solicitation o All States
 
 



13. Offering and Sales Amounts
Total Offering Amount $ 2750000 USD o Indefinite
Total Amount Sold $ 2750000 USD 
Total Remaining to be Sold $ 0 USD o Indefinite
 
Clarification of Response (if Necessary)
 Represents the aggregate gross proceeds from investors in connection with Issuer's registered direct offering of common stock and concurrent private placement of warrants, which were issued to investors for a single purchase price.


14. Investors
o Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering
0
  Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 3


15. Sales Commissions & Finders’ Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions$ 0 USD o Estimate
Finders' Fees$ 0 USD o Estimate
 
Clarification of Response (if Necessary)
  


16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
 $ 0 USD o
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more VistaGen Therapeutics Charts.
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more VistaGen Therapeutics Charts.

Vistagen Therapeutics, Inc. News

Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
Thursday 25 April 2024 (1 week ago) • Business Wire
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
Tuesday 9 April 2024 (4 weeks ago) • Business Wire
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
Monday 1 April 2024 (1 month ago) • Business Wire
Vistagen to Present at Stifel 2024 Virtual CNS Days
Monday 11 March 2024 (2 months ago) • Business Wire
Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 6 March 2024 (2 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 6 March 2024 (2 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 6 March 2024 (2 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 6 March 2024 (2 months ago) • Edgar (US Regulatory)
Form EFFECT - Notice of Effectiveness
Thursday 29 February 2024 (2 months ago) • Edgar (US Regulatory)
Vistagen to Present at TD Cowen 44th Annual Health Care Conference
Wednesday 28 February 2024 (2 months ago) • Business Wire
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Wednesday 14 February 2024 (3 months ago) • Edgar (US Regulatory)
Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Wednesday 14 February 2024 (3 months ago) • Edgar (US Regulatory)

More Vistagen Therapeutics, Inc. News Articles